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Coinfection with human immunodeficiency virus (HIV) and viral hepatitis leads to 
unfavorable health outcomes, making treatment of HIV difficult and increasing the odds 
of HIV transmission. The purpose of this study is to assess whether viral hepatitis (B and 
C) hinders HIV viral suppression and impacts the white blood cell count (CD4) when a 
person is concurrently infected with both viruses. The syndemics theory guided this 
study. Two research questions tested whether there was an association between 
coinfection with viral hepatitis and HIV viral load suppression. The research design was 
quantitative case-control with secondary data from 65,626 reports of HIV, HBV, and 
HCV at the Georgia Department of Public Health. Descriptive statistics and measures of 
association indicated that a coinfection with HBV or HCV was determined to be 
significantly associated with HIV viral load suppression. Persons coinfected with 
HBV/HIV were 1.45 times more likely to have achieved HIV viral load suppression than 
persons who were only infected with HIV (OR= 1.45, 95% CI 1.32-1.59, p= .0001). 
Those coinfected with HCV/HIV were 1.55 times more likely to have achieved HIV viral 
load suppression than those only infected with HIV (OR= 1.55, 95% CI 1.44-1.67, 
p=.0001). Coinfection with HBV was found to have a greater impact on CD4 cell counts, 
making persons infected with HBV/HIV 1.45 times more likely to be AIDS defining than 
HCV in individuals infected with HIV (OR= 1.45, 95% CI 1.34-1.67, p= .0001). Positive 
social change implications may include use of findings to support future prevention and 
control strategies in the coinfected population aimed at decreasing or controlling the 
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Chapter 1: Introduction to the Study 
Introduction 
Viral hepatitis is a group of communicable diseases that affects the liver by 
causing inflammation (CDC, 2014). The most common types of viral hepatitis in the 
United States are hepatitis A (HAV), hepatitis B (HBV), and hepatitis C (HCV; CDC, 
2014].  In the United States, there are between 2.2 and 4.7 million people infected with 
viral hepatitis, many of whom are not aware they are infected (HHS, 2020).  
Currently in 2020, viral hepatitis is the leading cause of liver cancer in the US 
(HHS, 2020). Liver cancer and other liver-related diseases resulting from long term liver 
damage secondary to untreated viral hepatitis affect approximately 4.4 million Americans 
nationwide (CDC, 2014). In the US, certain populations are more affected by viral 
hepatitis than others (HHS, 2013). Persons living with HIV/AIDS (PLWHA) are among 
those populations who are disproportionally affected by viral hepatitis (HHS, 2013). 
Human immunodeficiency virus (HIV) is a virus that attacks the body’s immune 
system. The infection is known to cause the selective loss of CD4 cells due to virus 
replication and subsequent cell destruction which causes the body to become more 
susceptible to other infections or infection-related cancers (DHHS Panel on Antiretroviral 
Guidelines for Adults and Adolescents, 2015). CD4 cell count is often used as an 
important measure of HIV progression and as one of the indications for treatment 
initiation (WHO, 2013). When the CD4 count drops below 200ml, a person is diagnosed 
with AIDS. A normal range for CD4 cells is about 500 to 1,500. The higher the CD4 
count, the better.  
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While effective antiretroviral treatment (ART) can significantly increase CD4 cell 
counts in most patients, there are certain populations who remain at comparatively low 
CD4 cell count levels (Kaufmann et al., 2013). Factors associated with poor CD4 
recovery have been extensively studied; examples of these factors include older age, 
ongoing HIV replication (Kaufmann et al., 2013), treatment disruption and non-
adherence to combined anti-retroviral therapy (cART) (Kaufmann et al., 2011), and late 
initiation of treatment (Tarwater et al., 2001). Since CD4 level forecasts mortality, and 
low CD4 cell count is associated with an increased risk of opportunistic infections, it is 
important to explore all possible factors that hinder immune recovery among HIV 
infected people (Lewden et al., 2007). 
The HIV viral load is a measurement of the amount of HIV circulating in the 
blood. The goal of HIV therapy is to prevent HIV from replicating in order to bring the 
viral population down to an undetectable level. When a person living with HIV begins an 
ART regimen, his/her viral load drops.  For almost everyone who adheres to his/her HIV 
medication as recommended, their HIV viral load will drop to an undetectable level in six 
months or less. This phenomenon is termed viral suppression. Continuing to take HIV 
medications as directed is imperative to stay virally undetectable or suppressed.  
Although a person’s viral load is undetectable, HIV is still present in the body. The virus 
lays dormant inside a small number of cells in the body.  However, persons who achieve 
and maintain viral suppression have effectively no risk of sexually transmitting the virus. 
The aim of HIV therapy is to sustain viral suppression for many years, which not only 
preserves future treatment options but reduces the risk of serious illness by 53%. Once 
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ART is stopped, the virus will return to a detectable level and start replicating again.  
HIV viral suppression is a powerful predictor of CD4 T-cell gains. HIV viral suppression 
is also important for people living with HIV to stay healthy, have improved quality of 
life, and live longer.  
Approximately 1.1 million people in the United States are living with HIV, and 
about 15% of them are not aware of their infection status (Mugavero et al., 2013). HIV 
and viral hepatitis share common modes of transmission, which include blood (most 
commonly through injection drug use) and unprotected sexual contact. Because of their 
common transmission modes, coinfections by these viruses is common (Alter, 2014). 
Significant proportions of PLWHA are coinfected with HCV, and others are chronically 
infected with HBV (Soriano et al., 2010). According to the Centers for Disease Control 
and Prevention (CDC), approximately one-third of HIV infected individuals are 
coinfected with hepatitis (HHS, 2013). This estimate equates to about 25% having 
HIV/HCV coinfections and about 10% having HIV/HBV coinfections (HHS, 2013).   
Problem Statement 
Medical comorbidities resulting in greater risk of liver cancer include obesity, 
diabetes mellitus, insulin resistance, hepatitis B virus infection and HIV infection 
(Chopra, 2014). Since persons infected with HIV are immunocompromised, the 
progression of viral hepatitis is accelerated to end-stage liver disease and hepatocellular 
carcinoma more than in those who are only infected with hepatitis (Vellozzi et al., 2011).  
Evidence suggests that HIV negatively impacts infections of HBV and HCV. 
Chopra (2014) suggested that when HIV is concurrently present with an HCV infection, 
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HIV speeds the progression of liver disease. Chun et al. (2012) also suggested that HIV 
has an adverse impact on HBV liver disease progression as well as an increased risk of 
liver cirrhosis.  
Although an increasing number of HIV-infected persons are taking ART, many 
do not achieve HIV viral suppression and remain at risk for Acquired Immune Deficiency 
Syndrome (AIDS) and more likely to transmit HIV. Understanding if HBV or HCV has a 
potential impact on HIV is limited. Taylor et al. (2012) previously suggested that a 
coinfection with HIV and viral hepatitis can lead to unfavorable health outcomes, making 
treatment of HIV difficult and increasing the risk of HIV transmission. However, Taylor 
et al.’s study did not consider how viral hepatitis impacts HIV CD4 cell counts nor HIV 
viral load suppression. This study assessed if viral hepatitis leads to unfavorable 
outcomes in HIV-infected persons by hindering the achievement of HIV viral 
suppression or by impacting HIV CD4 cell counts.  
Purpose of the Study  
The purpose of this quantitative, case control study was to assess if viral hepatitis 
(B and C) hinders HIV viral suppression and impacts CD4 count when a person is 
concurrently infected with both viruses. 
Research Questions  
The following are the research questions for this study: 
RQ1: Is there an association between coinfection with viral hepatitis and HIV 
viral load suppression in HIV positive individuals? 
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Ho1: There is no association between coinfection with viral hepatitis and HIV 
viral load suppression in HIV positive individuals. 
Ha1: There is an association between coinfection with viral hepatitis and HIV 
viral load suppression in HIV positive individuals.  
RQ2: Does the type of viral hepatitis (HBV or HCV) impact the CD4 count of the 
HIV infection?  
Ho2: The type of viral hepatitis (HBV or HCV) does not impact the CD4 count of 
the HIV infection. 
Ha2: The type of viral hepatitis (HBV or HCV) impacts the CD4 count of the HIV 
infection. 
Theoretical Framework 
This study was guided by the syndemics theory (Singer & Clair, 2003). The 
theory is used to understand the synergistic interactions of two or more diseases as they 
exist within the population with the presence of social and biological conditions. It is a 
valuable tool in the public health fight against HIV (Douglas-Vail, 2015). There are three 
constructs to this theory: (a) populations of interest, (b) social contexts shaping disease, 
and (c) biological synergism. The first construct requires that the two diseases of synergy 
must cluster in the same population to provide an opportunity for coinfection. The second 
construct encompasses the social conditions that influence individual and population 
health. The third construct occurs within the body of the individual when the two diseases 
are present. According to Singer and Clair (2003), actual biological synergism must occur 
between the two diseases (HIV and hepatitis), resulting in excess disease burden. There 
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are seven broad ways in which synergistic diseases interact within the body; they are 
enhanced contagiousness, accelerated virulence, greater expression of symptoms, 
physical alterations of the body’s immunology, alterations of emotions, and gene 
assortment between pathogens and iatrogenic interactions (Klein, 2011). This study 
focused on two of them, accelerated virulence and physical alterations of the body’s 
immunology. The two interactions guided this study by showing how the syndemic 
interaction of HIV, HBV, and HCV influence HIV viral suppression by increasing the 
amount of the HIV virus present in the body or by decreasing the CD4 count, thus 
inhibiting the achievement of HIV viral suppression.      
Nature of the Study 
This quantitative study had a case-control research design. In a case-control study, 
the outcome of interest is already known, and the researcher traces back to establish a 
relationship between the outcome and possible risk factors (Frankfort-Nachmias & 
Nachmias, 2008). In this study, the data were based on individuals that already have HIV, 
HIV/HCV, or HIV/HBV and are reported in Georgia’s Department of Public Health 
disease registries. A case-control design was appropriate for this type of study, because it 
is cost effective and timesaving and does not expose subjects to harm due to intervention 
effects. Case-control designs are also suitable for the analysis of multiple exposures, and 
more so in the investigation of rare diseases (Aschengrau & Seage III, 2014). 
Definitions of Terms 
CD4 cells: a type of white blood cell that fights infection in the body. In HIV infection, 
the virus destroys CD4 cells, lowering the body’s defenses to infection.  
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Comorbid infection or Coinfection: the presence of multiple infections in a host by 
multiple infectious agents (Cox, 2001).     
Electronic HIV and AIDS Surveillance System (eHARS): a web-based tool supported and 
developed by the CDC for state and local health departments for HIV/AIDS surveillance.  
Hepatitis: inflammation of the liver. The most common causes of viral hepatitis in the US 
are HAV, HBV, and HCV. HBV and HCV are common among those people who are at 
risk for or living with HIV (Alter, 2006).  
HIV: a virus that causes the HIV infections and over time may cause AIDS.  
State Electronic Notifiable Disease Surveillance System (SENDSS): created for the 
Georgia Department of Public Health (GDPH) for the reporting and surveillance of all 
notifiable diseases in Georgia. 
Viral Load (VL): the amount of HIV in an infected person’s blood. The higher the HIV 
level in the blood, the higher the VL, and the greater the risk the person has of becoming 
ill due to HIV. It is useful for measuring sustained response to ART (DHHS Panel on 
Antiretroviral Guidelines for Adults and Adolescents, 2015). 
Viral Suppression: HIV-1 viral load of less than 200 copies on the most recent VL test. 
Having viral suppression significantly decreases the rate of HIV transmission (Loutfy et 
al., 2013). 
Antiretroviral Therapy (ART): the use of HIV medicines to treat HIV infection. It is 
recommended for everyone who has HIV. ART helps people with HIV live longer, 
healthier lives and reduces the risk of HIV transmission.  
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Highly Active Antiretroviral Therapy (HAART): a form of treatment that uses a 
combination of three or more drugs to treat HIV infection.  
Assumptions 
Data collected by the GDPH were used to evaluate the hypotheses. The data set 
only contained persons living in Georgia at the time of diagnosis with either HIV or 
hepatitis. Because I did not collect the data, the accuracy of the data can only be assumed. 
Records cannot be reviewed for accuracy; however, GDPH has quality measures in place 
to ensure the validity and integrity of the data submitted. Therefore, I assumed that the 
quality measures in place are accurate and can minimize potential transcription error.   
A second assumption was that the data used in this study contained all reports of 
HIV and hepatitis in Georgia. Because HIV and hepatitis are reportable diseases in 
Georgia, it is required that all diagnosed diseases are reported to GDPH. Thus, it was 
assumed that the database contained all known adult disease diagnoses in the state.  
Scope and Delimitations 
The scope of this study was to compare the CD4 cell counts and HIV VLs of 
persons coinfected with HIV and HCV/HBV to those of persons who were only infected 
with HIV to assess whether HCV/HBV affects the achievement of viral suppression as 
well as to assess which type of hepatitis, B or C, is more virulent to the HIV infection by 
evaluating CD4 cell counts for a determination of AIDS.  
Limitations 
One limitation of this study was the data. There may have been missing laboratory 
data because of inadequate reporting, inadequate processing, or laboratory tests 
9 
 
performed outside of Georgia. All registered are mandated by state law to report 
laboratory results on HIV-related laboratory test to the Georgia DPH. However, some 
facilities may not comply or send only some test results and not others. This can result in 
an underestimation of the coinfected cases in Georgia. Another limitation is that the 
results of this study may not be generalizable, since the data were only collected from the 
coinfected population. The results, however, can be used as a reference point to other 
studies of the same population. 
Significance 
The goal of this study was to determine if HBV and HCV have an impact on HIV 
viral suppression and CD4 cell count among HIV/HBV and HIV/HCV coinfected 
persons. The HIV/viral hepatitis coinfection is a growing and evolving epidemic (Taylor 
et al., 2012). HBV and HCV are highly prevalent among the HIV infected population 
(Taylor et al., 2012). People with HIV who are coinfected with either HBV or HCV have 
an increased risk of life-threatening complications (CDC, 2014). Therefore, it is essential 
that health professionals be informed on how viral suppression and increased CD4 cell 
counts can be achieved in coinfected populations. When viral load is controlled (or 
suppressed), the risk of HIV transmission to others is greatly lowered (Mugavero et al., 
2013). This study could potentially be used to support future prevention and control 
strategies in the co-infected population aimed at decreasing or controlling the spread of 
HIV and other STIs in the United States. These strategies may increase individual 
knowledge of HIV, HBV, and HCV statuses, prevent new infections among HIV 
negative persons, reduce transmission from persons living with HIV, and enhance 
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response capacity and intensive data-to-care activities to support sustained viral 
suppression.  The results may also provide insight on whether a coinfection with HBV or 
HCV affects HIV viral suppression in a person infected with HIV, which can be used to 
improve health outcomes for persons living with HIV through increasing screenings and 
provide better access to care.  
Summary 
The purpose of this study was to examine if either or both HBV and HCV affect 
HIV viral suppression in a person who is infected with HIV. This study used quantitative 
methodology. Data were extracted from the eHARS and SENDSS databases of the 
GDPH.  The study was grounded by the syndemics theory (Singer & Clair, 2003), which 
allows researchers to investigate the synergistic interactions of two or more diseases as 
they coexist within the population alongside social and biological conditions. The results 
of this study may potentially be used to improve the health outcomes of persons living 
with HIV/AIDS.  
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Chapter 2: Literature Review 
Introduction 
The use of ART has led to great reductions in HIV related morbidity and 
mortality in HIV infected individuals (Cooper & Cameron, 2014). However, alongside 
ART’s success has been the succeeding emergence of comorbidities, such as STIs. In the 
presence of an STI, HIV may be transmitted at a rate that is up to five times greater than 
in a person who does not have an STI (Mehendale et al., 2015). 
 HCV and HBV, due to their high presence in the HIV positive population, are 
among the leading causes of morbidity and mortality in the HIV positive population 
(Matthews et al., 2014). The hepatitis viruses have been known for their potential 
association with poor HIV health outcomes (Matthews et al., 2014). Coinfection of HIV 
positive individuals with HBV and HCV is a global problem of increasing concern, 
despite the availability of successful strategies for both their prevention and treatment. 
Several studies have examined the impact of HCV and HBV on HIV. While most have 
found that these viruses have no impact on the HIV virologic response to ART, there are 
conflicting reports regarding immunologic response. 
Literature Search Strategy 
I conducted the literature search using the Walden University library’s online 
databases and journal articles from the years 2014 until present. First, I ordered the 
databases by subject. I searched journals categorized as health sciences and/or nursing. 
The databases found to be most useful were Health Sciences: A Sage Full Text Journal, 
MEDLINE, and Academic Search Premier. Other databases searched included Google 
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Scholar, Health and Medical Complete, and Nursing and Allied Health Source. I 
searched each of these databases using the same search terms. I reviewed these databases 
multiple times during the search period to identify newly added articles. Several terms 
were included in the database searches. HIV was used as well as the expanded name of 
human immunodeficiency virus. AIDS and its expanded name acquired immunodeficiency 
syndrome were also included. HIV and hepatitis B and hepatitis C were used individually 
and in combination. Comorbid infection was also searched with HIV and Hepatitis B and 
C. This same search was also conducted using coinfection as a synonym for comorbid 
infection. Subsequently, sexually transmitted disease and infection were also used as 
search parameters in conjunction with comorbid illness and coinfection to garner some 
general articles about the effects of coinfection with a sexually transmitted disease (STD) 
on health. 
Organization of the Review 
First, I review the theoretical framework for the study. Next, background 
information on HIV and Hepatitis B and C diseases (treated as separate and unique 
infections) is presented. The presentation includes relevant statistics and a summary of 
research studies associated with the infections. Following is a general discussion of 
HIV/HBV and HIV/HCV coinfection and its associated background, statistics, and 
studies. Finally, the literature review concludes with a consideration of the impact of this 




 The syndemic theory was identified during the mid-1990s by anthropologist 
Merrill Singer (Klein, 2011). Singer was the first researcher to identify a syndemic in 
public health research (Wilson et al., 2014). Syndemic refers to the tendency for multiple 
epidemics to co-occur and interact with one another, with each one worsening the effects 
of the others (Singer, 2009). Syndemics occur when health-related problems cluster by 
person, place, or time. Syndemic also focuses on health disparities and the social 
conditions that affect them. The concept of syndemics represents an acknowledgment of 
the fact that many diseases and social problems worsen the effects of others already being 
experienced by their host. Syndemics are prevented by the control of each disease that 
plays a role in it, as well as the prevention and control of the forces that bound the two 
diseases together (Singer & Clair, 2003).  
 The syndemic theory was created in attempts to identify a “big picture” approach 
in epidemiological and public health thinking. Singer wanted to understand the 
determinant interconnections among pressing health problems, sufferer and community 
understandings of the illness(es)/disease(s) in question, the relevant social, political, and 
economic forces in play, and the environmental conditions that contributed to the 
development of ill health. The syndemic theory can be conceptualized with the following 




The Populations of Interests  
 The CDC described a syndemic as two or more epidemics in the same population, 
interacting to create an opportunity for co-infection and synergism which ultimately lead 
to excess burden of disease (Douglas-Vail, 2015). For example, frequently HIV and 
Mycobacterium tuberculosis (MTb) are clustered in the same population. When this 
happens, opportunities for individuals to be coinfected spiral upward due to the presence 
of both in the same population. Researchers have found that coinfection with HIV and 
MTb synergically interacts, leading to deadly consequences by lessening the survival 
time of coinfected individuals compared to individuals with just HIV or MTb (Dye et al., 
1999). Another example of a synergistic effect can be seen in individuals who are 
suffering from asthma, which increases their chances of developing a coinfection with 
respiratory syncytial virus and influenza A virus, thus resulting in induced asthma attacks 
of greater severity (Zhoe et al., 2009).   
Social Contexts Shaping Disease 
 The term syndemic goes beyond the idea of disease clustering in a particular 
location or population. It highlights the importance of the social conditions that influence 
the health of individuals and populations. Evidence suggests that social conditions are 
closely related to health outcomes (Currie, 2012). According to Currie (2012), 
determinants such as socioeconomic status, geographical location, gender, race, ethnicity, 
age, diet, water, sanitation, residence, access to health care, discrimination, stress, 
violence, and criminal justice systems are some of the social causes of syndemics. Social 
contexts outline not only the spread of disease, but also affect access to resources for 
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coping with disease burdens (Douglas-Vail, 2015). For example, research has shown that 
the HIV/HBV coinfection interaction can lead to poor health outcomes in the coinfected 
individual, but Gomez-Gonzalo et al. (2001) underlined that the impact the viruses have 
on one another is mediated by individual biology and age, nutritional status, and access to 
medical care of the coinfected individual. Another example of social context would be 
that individuals living in poverty have an increased likelihood of exposure to TB due to 
overcrowding in poorly ventilated habitations. Once infected, these individuals would be 
more likely to develop active TB because they are already weakened from other 
infections and malnutrition (Douglas-Vail, 2015).  
Biological Synergism 
 The final concept of the syndemic theory is biological synergism. This is 
described as the interaction that occurs between two diseases within the body of the 
individual. Biological synergism is not the same as a mere comorbidity or coinfection. A 
coinfection refers to concurrent diseases without synergistic effects. In order to be 
defined as syndemic, the two diseases must result in excess burden when present 
concurrently. Some ways in which syndemic diseases interact in the body include 
enhanced contagiousness, accelerated virulence, greater expression of symptoms, 
physical alterations of the body, and gene assortment between pathogens and iatrogenic 
interactions (Douglas-Vail, 2015). An example of this concept is seen in the interaction 
between the two viruses HIV and HBV. Research suggests that HIV and HBV may have 
physical interactions at the cellular level in coinfected individuals (Ockenga et al., 1997). 
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HBV infects the T-lymphocytes, the primary cellular target of HIV, which in turn 
contributes to faster HIV replication and a more rapid progression to AIDS.  
 The full impact of HIV/AIDS stems from its syndemic interaction with various 
other diseases. The virus works together with a range of pathogens, such as hepatitis, TB, 
malaria, leishmaniasis, herpes and other STDs. HIV/AIDS also interacts unfavorably 
with non-infectious diseases and disorders, such as kidney disease, food deficiency, 
behavioral health problems, and cardiovascular diseases (Singer 2009). A study by 
Pugliese et al. (2002) showed that a syndemic interaction between human papillomavirus 
and HIV triggers greater chances of the development of cervical cancer in women when a 
coinfection by the two viruses is present. In another study, Pugliese et al. (2002) showed 
that when the effect of the coinfection with HIV and human herpesvirus type 8 was 
investigated among women, findings suggested that coinfection led to accelerated 
deterioration of the immune and hematopoietic systems.    
 The syndemic theory is a valuable tool in the public health fight against HIV. The 
theory is used to understand the connections between diseases by examining routes of 
transmission and interrelated health problems which result in excess disease burden 
(Singer, 2010). Researchers rely on the syndemic theory to understand the forces that tie 
diseases together. It suggests that medicine and public health should shift focus from 
individual risk behaviors to relationships, context, and processes (Singer, 2010). One of 
the greatest strengths of the syndemic theory is its ability to inform prevention and 
treatment programs. The syndemic approach aims to develop a richer understanding of 
disease prevention using broad public heath-based initiatives for the creation of programs 
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to address and lessen the impact of syndemics currently affecting populations and 
programs designed to predict and prevent the emergence of future syndemics. This study 
focused on the biological synergism component of the syndemic theory.  
Human Immunodeficiency Virus 
Originally seen in the 1980s, HIV is the causative agent of AIDS (Sarngadharan 
et al., 1984). HIV has an attraction for the body’s T cells. These are the white blood cells 
responsible for the cell-mediated immunological response, commonly referred to as CD4 
cells. CD4 cells are instrumental in the body’s ability to intervene against disease 
acquisition and are required for the proper functioning of the human immune system. The 
virus enters these white blood cells via CD4 receptors. The virus then uses mechanisms 
in the white blood cell to replicate itself and spread throughout the body, slowly killing 
all the infected person’s T cells. Lower CD4 counts mean a higher likelihood of health 
issues and sometimes death related to HIV, as the infected person’s immune system no 
longer functions to fight off infection. In weakened immune systems, opportunistic 
infections that would typically not occur in healthy individuals become great threats. 
These infections become easily acquired and difficult to treat. The infections may often 
leave an HIV-infected individual severely ill and, if unmanaged, with a high risk of death 
(CDC, 2016). 
HIV resides in white blood cells that can be found in some body fluids, such as 
blood, semen, breast milk, and vaginal fluid. Thus, one of the primary pathways of 
acquisition is transmission through sexual intercourse. Other transmission pathways 
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include intravenous drug use (IDU), vaginal birth, and breast feeding by HIV-positive 
mothers. There is currently no cure or vaccination for HIV. 
As of December 2019, an estimated 38.0 million people globally were living with 
HIV. 1.7 million became newly infected in 2019, and 690,000 died of an HIV-related 
illness (UNAIDS, 2020). Although HIV transmission has declined since 2001, more 
people are living with HIV than ever before due to the use of ART (Platt et al., 2015). In 
2018, the CDC estimated 37,968 incident cases of HIV in the United States. Of these 
cases, 70% were among gay and bisexual men or men who sleep with men (MSM). 
African Americans, Hispanics and Caucasians were responsible for 44%, 25% and 28.3% 
of the new infections, respectively (CDC, 2020). Adult women with high-risk 
heterosexual behavior accounted for 20.0% of the new infections, and men with similar 
high-risk heterosexual behavior accounted for only 10.3% of new infections. Other risk 
categories included IDU (10.0%) and a category classified as other (0.1%) that included 
hemophiliacs, blood transfusion recipients, perinatal exposure, or unknown/unreported 
exposure (CDC, 2020).  
The age distribution of all HIV cases in 2018 revealed substantial increases in 
case numbers beginning at age 20. There were 14,740 new cases of HIV for those 
between the ages of 20 and 29 years, and 9,943 for those in the age group between 30 and 
39 years. Cases began to decline for those between 40 years and 49 years (6,490 new 
cases), and for persons aged 65 years and older with fewer than 2,000 cases (CDC, 2020). 
Geographically, the South had the highest incidence rate for HIV in 2018 with 15.6 cases 
per 100,000 people (CDC, 2020). In the South, Georgia leads with the highest incident 
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rate of HIV diagnosis, 23.8 cases per 100,000. Disparities in HIV are also found in 
socioeconomic status, defined in terms of education, income, levels of poverty, 
educational attainment, and access to care. Poverty is associated with low educational 
attainment, low income, and reduced access to care. Persons with lower income tend to 
have lower education, less access to care, and increased HIV incidence (Fenton, 2004). In 
the United States, rates of HIV among MSM were still the highest among all subgroups 
(CDC, 2020); this likely explains the large amount of research focusing on MSM. 
Hepatitis B Virus 
Hepatitis B is a liver infection caused by HBV, which is transmitted through 
blood, semen, or other bodily fluids through sexual contact; sharing needles, syringes, or 
other drug-injection equipment; or from mother to baby at birth. For some people, 
hepatitis B is an acute or short-term illness, but for others, it can become a long-term, 
chronic infection. Chronic Hepatitis B can lead to serious health issues, like cirrhosis or 
liver cancer. The best way to prevent Hepatitis B is by getting vaccinated. 
In 2018, an estimated 257 million people are living with HBV. In 2018, a total of 
3,322 cases of acute HBV in the Unites States was reported to CDC. As of 2018, CDC 
estimated that almost 862,000 persons in the United States had chronic HBV. The 
incidence of HBV infection differs significantly by race and ethnicity, with the highest 
rates being among Blacks, and rates being higher among Hispanics than non-Hispanics. 
Incidence also varies by age, with the highest rates reported among persons 20-39 years 
of age. In Georgia, there were 1,421 reported incident cases in 2018. The most common 
risk factors reported in Georgia were IDU, multiple sex partners, and MSM.  
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Hepatitis C Virus  
HCV is an RNA virus that causes acute and chronic liver infection. In the US, 
about two- thirds of HCV-infected people become chronic carriers, while the remaining 
one-third may spontaneously clear the virus without requiring any treatment. HCV 
infection is the most common chronic blood-borne infection in the United States. In 
2005, more than 184 million people were estimated to have been infected with HCV. By 
2014, this number had declined to 115 million as a result of improved screening of blood 
donations and decreased IDU (Platt et al., 2016).   
Chronic HCV infection is a major cause of mortality and morbidity across 
countries. There are an estimated 177 million people infected worldwide (Petruzziello et 
al., 2016).  An estimated 2.7-3.9 million people in the United States have chronic 
hepatitis C. HCV infection occurs among persons of all ages, but the highest incidence of 
acute Hepatitis C is found among persons 20-39 years. African Americans and Whites 
have similar incidence rates of acute disease, with higher rates in persons of Hispanic 
ethnicity. In Georgia, there were 5,451 reported incident cases in 2018. The most 
common risk factors reported were IDU, multiple sex partners and MSM.  
HIV/HBV Coinfection 
The viral diseases of hepatitis and HIV/AIDS are known as the twin epidemics, 
due to their similarities and consequences of coinfection (Highleyman, 2003). A growing 
body of literature indicates that HIV positive individuals are more likely to be infected 
with HBV than HIV negative individuals, possibly as a result of shared risk factors 
(Mallet et al., 2011). There is also evidence that HIV positive individuals who are 
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subsequently infected with HBV are more likely to become HBV chronic carriers and 
have a high HBV replication rate. In addition, it is evident that immunosuppression 
brought about by HIV infection may cause reactivation or re-infection in those previously 
exposed to HBV. Furthermore, HIV infection exacerbates liver disease in HBV 
coinfected individuals, and there is an even greater risk of liver disease when HIV and 
HBV co-infected patients are treated with ART. Complicating matters further, there have 
been several reports linking HIV infection to "sero-silent" HBV infections, which present 
serious problems for diagnosis, prevention, and control (Platt et al., 2015) (Marine-
Barjoan et al., 2014). 
There are several studies that suggest that HIV immunosuppression may reduce 
liver damage as a result of a less aggressive HBV specific immune response, and this is 
supported by reports of a reduction in icteric illness in acute HBV infections in HIV 
positive patients (Highleyman, 2003). However, HIV infection has been found to 
exacerbate liver disease, with an early study finding death from liver failure in four of 
five HIV/HBV coinfected individuals compared with two of six HIV negative HBV 
infected individuals (Matthews et al., 2014).  
HIV/HCV Coinfection 
Of special concern regarding HIV coinfection is the HCV. Both HIV and HCV 
are rapidly replicating RNA viruses, and both are transmitted via blood contact. A 
common route of transmission is multiple sharing syringes by injection drug users 
(Singer et al., 2000). The prevalence of HCV in HIV-infected populations is highest in 
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IDU, followed by MSM and pregnant or heterosexually exposed populations (Platt et al., 
2015). 
Many studies suggest that HIV infection leads to hepatitis infections that are more 
aggressive than those in individuals not infected with HIV (Singer, 2009). The interaction 
between HIV and HCV in coinfection affects the transmission and natural history of the 
HCV infection. HCV transmission proficiency increases in the presence of the HIV 
infection (Platt et al., 2015). People living with HIV who do not receive ART have 
reduced chances of naturally clearing the HCV infection, have increased HCV VLs, and 
experience more rapid HCV disease progression than those without HIV infection (Platt 
et al., 2015). In HIV/HCV coinfected individuals, successful ART leading to viral 
suppression of HIV replication is associated not only with lower rates of AIDS-related 
disorders but also with slower progression of liver fibrosis and lower mortality from liver 
disease (Marine-Barjoan et al., 2014). 
In contrast to HIV negative individuals, HIV positive individuals infected with HCV 
usually become chronic carriers (Thomas et al., 2000). Among those infected with HCV, 
approximately 20–45% spontaneously clear the infection without treatment; this 
proportion is lower in HIV coinfected individuals due to weaker HCV specific immune 
responses (Moqueet et al., 2015). Although ART has been found to improve HCV 
outcomes in coinfected patients, the HCV coinfection may complicate HIV treatment.  
Evidence have suggested an increased risk of drug related hepatoxicity in those receiving 
ART for HIV infection (Taylor et al., 2012). Such negative outcomes appear to be as a 
result of the inability of the immune system to contain HCV when under attack from 
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HIV. Even in cases where it seems that the body has been able to clear HCV, as the 
immune system deteriorates, HCV replication restarts (Kim et al., 2006). 
The question of the impact of HCV on the natural history of HIV disease remains 
of considerable interest. Prior to the availability of combination ART (pre-1996), 
increased rates of HIV disease progression largely masked any effects of HCV disease on 
HIV. Since then, Greub et al. (2014), reported from the Swiss Cohort Study that HCV 
infection was associated with a 70% increased probability of progression to a new AIDS 
defining event or death. Some studies have confirmed his findings, such as Bonacini et al. 
(2004), which found that the hepatitis viruses do in fact have potential associations with 
poor HIV outcomes, while other studies refute these findings (Kim et al., 2006). 
There are many ways that HCV could impact HIV disease progression; for 
example, liver disease may preclude the use of ART because of hepatotoxicity. Many 
coinfected individuals, because of sociodemographics or uncontrolled addiction, simply 
never access ART and die of AIDS. It is also possible that HCV has a direct influence on 
HIV infection, although the mechanism of action is yet unknown. As people with HIV 
live longer, HCV related liver disease in coinfected patients is becoming a major cause of 
morbidity and mortality. However, the burden of HIV/HCV coinfection is poorly 
understood. 
HIV and Viral Suppression 
Viral suppression is a measure that indicates a progression along the HIV care 
continuum. When a person living with HIV begins an ART regimen, his/her HIV VL 
decreases. For almost everyone who takes his/her HIV medication daily as prescribed, the 
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HIV VL will decrease to an undetectable level in six months or less. A person’s HIV VL 
is considered undetectable when all VL test results are undetectable for at least six 
months after the first undetectable test result. Continuing to take HIV medications as 
directed is imperative for the HIV VL to remain undetectable. Persons living with HIV 
who take antiretroviral medications daily as prescribed and who achieve and then 
maintain an undetectable VL, have effectively no risk of sexually transmitting the virus to 
an HIV negative partner.  According to recent data, of the estimated 1.2 million people 
infected with HIV in the United States, almost 210,000 are virally suppressed (Gardner et 
al., 2011).  
Persons with high initial CD4 counts have a greater likelihood of reaching HIV 
viral suppression (Yehia et al., 2014). The CD4 cell count is important, because it allows 
clinicians to monitor how well a person’s body is responding to ART and it provides an 
overall status of the persons’s immune system (Brenan et al., 2013). The CD4 cell count 
is used clinically in determining how quickly ART needs to be initiated and when to start 
and discontinue prophylaxis for opportunistic infections and is a predictor of disease 
progression and survival (DHHS Panel on Antiretroviral Guidelines for Adults and 
Adolescents, 2015). CD4 cell count is also used to monitor ongoing disease progression 
and severity and to determine stage of HIV infection (Stage 1 is a CD4 count of greater 
than or equal to 500 cells/μL or a CD4 percentage of total lymphocytes of greater than 
26, Stage 2 is a CD4 count of 200- 499 or CD4 percentage of total lymphocytes of 14 – 
25, and Stage 3 is a CD4 count of less than 200 or CD4 percentage of total lymphocytes 
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of less than 14 (Selik et al., 2014). CD4 cell count is a strong predictor of death but is 
modified by HIV viral suppression and time on ART (Brennan et al., 2013).  
Literature Related to the Content 
Several studies have investigated the health outcomes of an HIV coinfection with 
HBV or HCV; however, to date, very few have researched the effects of the CD4 cell 
count on the coinfection. The data in this area, most published over a decade ago and in 
both the pre-combination and post-combination ART eras, are mixed in their findings, 
largely using endpoints of AIDS defining events or death.  
A search of the literature showed that there are conflicting reports on the effect of 
HBV/HCV infection on the natural history of HIV disease. The Swiss HIV Cohort Study 
for example found that in the first year of initiating ART, HCV infected individuals had 
smaller increases in CD4 cell counts than HCV negative individuals (Kaufmann et al., 
2003). The EUROSIDA study did not find an effect of HCV on HIV disease progression, 
but there was an increased risk of liver-related deaths among HCV coinfected individuals 
(Rockstroh et al., 2005).   
In Piroth et al. (1998) longitudinal study, immunologic progression was examined 
in HIV/HCV coinfected persons. One hundred and nineteen HIV infected persons 
coinfected with HCV, and 119 matched individuals infected with only HIV were 
included in the cohort. Clinical progression was defined as one or more of the following: 
a 20% loss of body weight; an AIDS-defining illness (for non-AIDS patients); and/or 
death (except by accident, suicide or overdose). Immunological progression was defined 
as a 50% decrease in the initial CD4 T-cell count (for patients with an initial count > 100 
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x 10(6) cells/l). Effects of HCV coinfection were evaluated using Kaplan-Meier survival 
analysis, and significance was tested using univariate (log-rank and Peto's tests) and 
multivariate methods (Cox regression). Clinical progression was more rapid in HIV/HCV 
coinfected patients than in HIV positive patients not infected by HCV in that CD4 cell 
counts of more than 600mL declined when HCV was present. This might suggest a 
greater impact of HCV on HIV disease progression in early HIV infection.   
Greub et al. (2014) found that after effective ART, HIV/HCV patients had a 
modest increased risk of progression to a new AIDS defined illness or death. In this 
study, 1157 patients (37.2%) were coinfected with HCV. In multivariate Cox regression, 
the probability of progression to a new AIDS-defining clinical event or to death was 
independently associated with HCV infection (hazard ratio 1.7 [95% CI 1.26-2.30]). 
HCV infection was associated with a smaller CD4 cell recovery (hazard ratio for a CD4-
cell count increase of at least 50 cells/microL=0.79 [0.72-0.87]). 
In a study by Sarkar et al., (2016), 1331 confirmed HIV positive individuals were 
initiated on ART. Among the participants, 1253 were only infected by HIV, and 78 were 
HIV/HBV coinfected. All participants, before starting ART, were subjected to baseline 
mandatory laboratory testing [CD4 count, complete hemogram, liver function tests 
(LFT), fasting blood sugar, blood urea, serum creatinine, venereal disease research 
laboratory (VDRL), hepatitis B surface antigen (HBsAg), routine stool and urine analysis 
and chest X-ray [posterior anterior (PA) view]. HIV/HBV coinfected individuals had 
more advanced HIV disease (WHO clinical stage 3 and 4) than HIV- only infected 
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individuals (37.1% vs. 19.9%). CD4 cell count was non-significantly lower in coinfected 
patients. 
A study done by Bani-Sadr et al. (2014), examined the impact of HCV-related 
characteristics such as genotype, VL or liver fibrosis on the chances of achieving 
sustained HIV suppression in coinfected patients. Eight hundred ninety-seven patients 
were examined to determine the relationship between HIV/HCV-related and social 
behavioral characteristics and HIV sustained viral suppression (SVS). The main outcome 
variable was HIV SVS, defined as at least two consecutive undetectable HIV VLs. 
Among the 897 HIV/HCV coinfected patients, 419 (47%) had received HCV therapy at 
least once, and 103 patients (25%) had experienced an HCV sustained virologic response 
(SVR). Results showed that HCV SVR was associated with a higher likelihood of 
achieving HIV SVS.  
Van Santen et al. (2019) aimed to assess the effect of incident HCV infection and 
its timing relative to HIV seroconversion in HIV positive MSM on their subsequent CD4 
cell count and HIV VL. HCV/HIV coinfected MSM were matched to HIV only infected 
MSM by time of HIV infection and combination ART use. Two-hundred fourteen HIV 
infected and 147 HCV/HIV coinfected MSM were matched to 3954 controls, HIV only 
infected MSM. The timing of HCV seroconversion relative to HIV seroconversion had 
no evident effect on HIV VL or CD4 cell count. In the first 2-3 years following HCV 
infection, CD4 cell counts were lower among HCV/HIV coinfected MSM but became 
similar to counts in HIV only MSM years later. The authors concluded that regardless of 
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the duration of HIV infection when HCV is acquired, CD4 cell counts are temporarily 
lower following HCV, even when on ART. 
In a study done by Aibibula et al. (2018), the association between poor HIV viral 
control and immune recovery among person coinfected with HCV/HIV was examined. A 
total of 725 participants was enrolled between 2012 and 2015. At baseline, 52% of the 
participants reported having depressive symptoms, and 75% had an undetectable HIV VL 
(HIV virally suppressed).  Participants experiencing depressive symptoms had 1.32 times 
(95% CI: 1.07, 1.63) the risk of having detectable HIV VL (not HIV virally suppressed) 
but had comparable CD4 count to people who did not experience depressive symptoms. 
The presence of depressive symptoms was thus a risk factor for incomplete, short-term, 
HIV viral suppression among people co/infected with HIV/HCV.  
Aibibula et al. (2018) also examined the impact of food insecurity on HIV viral 
VL and CD4 cell count among people coinfected with HIV and HCV. There were 725 
HIV/HCV coinfected people with 1973 person-visits over 3 years of follow-up in the 
study. At baseline, 23% of participants experienced moderate food insecurity, and 34% 
experienced severe food insecurity. The proportion of participants with undetectable HIV 
viral load was 75%, and the median CD4 count was 460 cells/μL. Participants 
experiencing severe food insecurity had 1.47 times the risk of having detectable HIV 
viral load compared with people who were food secure. These findings provide evidence 
of the negative impact of food insecurity on HIV viral load and CD4 cell count among 
HIV/HCV coinfected people. 
29 
 
Cescon et al. (2014) compared HIV treatment outcomes and survival between 
HIV/HCV coinfected individuals with and without IDU history. This study was restricted 
to 1254 participants with HIV/HCV coinfection and known IDU history. During a 
median follow-up time of 3.8 years, 217 deaths were reported. In adjusted multivariable 
analysis, individuals with IDU history were significantly less likely to achieve virologic 
suppression and CD4 cell count recovery and had a significantly higher risk of mortality.  
Despite the adverse clinical consequences of HIV/hepatitis coinfection, the 
mechanisms by which these two viruses interact at the cellular level remain largely 
unexplored. At present, the literature suggests that the major contribution of hepatitis to 
coinfected individuals is accelerated liver disease and increased HIV/AIDS-related 
complications. A better understanding of the interactions between these two viruses is 
vital to the development of novel treatment strategies to control HIV/hepatitis 
coinfections.  
Literature Related to Methods 
Epidemiological studies may be experimental, quasi-experimental, or 
observational. Both experimental and quasi-experimental involve manipulation of a study 
factor, while an observational study observes naturally occurring phenomena to make 
inferences (Friis & Sellars, 2004,). Research methodologies include qualitative, 
quantitative and mixed methods. Among the quantitative studies reviewed were 
retrospective studies, cohort studies, and cross-sectional studies (Rao et al., 1998; Stekler 
et al., 2005; Shah et al., 2002). Like the proposed research, some of the studies 
retrospectively examined medical records and charts. An advantage to a medical record 
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review is that the data are already present and do not have to be collected by the 
researcher.  
In a case-control study in African American women, the researchers evaluated 
social, behavioral, and epidemiologic risk factors which potentially predispose a person 
to HIV (Forna et al., 2006). Focus groups were used to gather information regarding HIV 
behavioral risk factors and recommendations to minimize transmission among African 
American women. The case-control study design allowed the researcher to evaluate risk 
factor data as well as presented topics for future investigation as described by the 
participants.  
In a case-control study conducted by Resino et al. (2014), phenotypic and 
functional parameters of immune restoration were evaluated in 27 HIV-infected patients 
on HAART. The patients were compared to 11 HIV infected controls that never had less 
than 500 CD4 cell counts. The participants were followed for 18 months. Results showed 
that the cases (HAART patients) with a previous state of severe-moderate 
immunosuppression normalizing their CD4 cells had an incomplete immune 
reconstruction after HAART.    
Skiest et al. (2006), used a case-control methodology to study the impact of 
comorbidity on the course of HIV disease in older patients as compared to a matched 
cohort of younger patients. Forty-three HIV infected patients, 55 years and older, were 
compared to a randomly selected group of 86 patients 45 years old, matched by date of 
HIV diagnosis. Data were collected on non-HIV-related morbidity, initiator of HIV 
testing, HIV stage at time of HIV diagnosis (TOHD), AIDS defining diagnoses, AIDS-
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related illnesses (ARI), observed AIDS-free interval, survival, and frequency of HIV-
related and unrelated hospitalizations. Results showed that older HIV infected patients 
presented with more advanced disease, which may have been due to lack of HIV 
awareness in this population, had a shorter survival and had more HIV- and non-HIV-
related comorbidity than the younger patients. The more rapid course and decreased 
survival in the elderly may have been related to possible comorbidity confounders. 
Lawrence et al. (2001), performed a case-control study to investigate the impact 
of early untreated HIV infection on chronic HCV. Medical records were examined for 
HIV-infected patients who had a medical exam during 1995-1996. Patients were screened 
for IDU, CD4 cell count, ART, and positive anti-HCV antibody. Thirty-eight eligible 
HIV-infected patients (cases) and 38 HCV infected patients without HIV (controls) were 
randomly matched by age, sex and duration of HCV infection. The study found that early 
treated HIV infection is associated with higher HCV viremia and more severe liver injury 
in IDUs with chronic HCV.   
Ying Yu et al. (2018), used a case-control study to examine the HCV viral loads 
among IDUs with HCV infection, HCV/HIV coinfection, and HIV/HBV coinfection. 
Among the 45 IDUs recruited, 27 were HCV mono-infected, 9 were HCV/HIV 
coinfected; 7 were HCV‐HBV coinfected, and 2 were seronegative for HCV, HBV, and 
HIV infection. A control group of 180 age and gender matched chronic HCV infected 
non IDU patients was enrolled. Results showed that the HCV RNA levels in IDUs with 
HCV/HIV coinfection were significantly higher than those in the control group, the  
IDUs with HCV only infection group, and IDUs with HIV/HBV coinfection group (P < 
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0.001, P < 0.001, and P < 0.001, respectively). IDUs with HCV/HIV coinfection suffered 
worse outcomes. Programs for how to block HIV transmission in this group need to focus 
on the education and routine check- ups of those with risky sexual customs and practices. 
 A case-control study by Darraj et al. (2018), was performed to characterize the 
factors associated with decreased immunological response among Manitoba's HIV 
population. The case-control study included HIV patients with immune reconstitution 
failure despite suppression of HIV replication by ART. Immune reconstitution failure 
was defined by CD4 cell count increase from baseline of less than 100 CD4 cells/mm or 
lack of increase to above 200 CD4 cells/mm within one year of viral suppression. A total 
of 42 individuals who met the definition of immune reconstitution failure were assigned 
as cases. Controls were 31 patients comprising a range of ages and CD4 cell counts like 
those of the cases. Results showed that age and a low CD4 cell count before the start of 
ART were possible predictors of immune reconstruction failure.   
 Advanced HIV infection despite sustained viral suppression by HAART is a risk 
factor for poor immunologic recovery. However, some patients with advanced infection 
do recover. Kim et al. (2015), examined predictive factors of immunologic recovery in 
advanced HIV patients showing sustained viral suppression. A case-control study was 
conducted in HIV-infected adult patients with an HIV diagnosis of 4 years or longer who 
were receiving HAART. Advanced HIV infection was defined as a baseline CD4 T cell 
count < 200/mm or AIDS. Immunologic responders were defined as patients showing 
immunologic recovery (CD4 cell counts ≥ 500/mm at 4 years with HAART). Of 102 
eligible patients, 73 had advanced HIV, and 33 showed immunologic recovery. The 
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median CD4 slopes during 0 to 6 and 0 to 12 months of HAART in the advanced patients 
were significantly higher in responders than in non-responders. Multivariate analyses 
showed opportunistic infections at the start of HAART were independently associated 
with immunologic recovery. Coinfection with HCV and HBV were among the factors 
that were associated with a poor immunologic response.  
 Brites-Alves et al. (2015), also used case-control methodology to compare virally 
suppressed HIV patients according to restoration pattern: adequate response (AR), partial 
response (PR), and inadequate response (IR). A total of 293 patients, 92 cases and 189 
controls, (89 AR, 112 PR, and 92 IR) were evaluated. A previous diagnosis of HCV or 
Tb was associated with IR. Longer time on ART was associated with a greater chance of 
AR, but logistic regression identified coinfection by HCV as the main factor associated 
with abnormal CD4 ratio. They concluded that previous HCV diagnosis significantly 
increases the risk of abnormal CD4 cell count. 
Summary 
In the United States, there are between 2.2 and 4.7 million people infected with 
viral hepatitis (HHS, 2020). Persons living with HIV/AIDS (PLWHA), are among those 
populations who are disproportionally affected by viral hepatitis (HHS, 2013). HCV and 
HBV, due to their high prevalence in them, are among the leading causes of morbidity 
and mortality in the HIV positive populations (Matthews et al., 2014). The literature has 
revealed that HIV infection leads to hepatitis infections that are more aggressive than 
those in individuals not infected with HIV, but a focus on the effects of HBV/HCV on 
HIV viral suppression and CD4 cell counts has not been fully researched. HIV viral 
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suppression is the goal of ART. People living with HIV who achieve and maintain an 
undetectable VL have effectively no risk of sexually transmitting the virus to an HIV 
negative partner. Given that HBV and HCV are heavily prevalent in the HIV population, 
it is essential to understand if a coinfection by either of these viruses effects the 
achievement of HIV viral suppression and leads to decreased CD4 cell counts.   
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Chapter 3: Research Method 
Introduction 
In this chapter, I describe the research methodology used for this study. The goal 
of this chapter was to give a description of the study design and secondary data sources. 
This chapter also includes the data collection procedure and the data analysis plan. This 
chapter concludes with a summary of the research methods used. 
Research Design & Approach 
An observational approach was used as opposed to an experimental approach, as 
variable manipulation in the latter would be both illogical and unethical. The study 
sample included those with reported HIV and/or hepatitis data available in the GDPH 
eHARS and SENDSS databases between 2012 and 2016. 
The case-control design methodology was used for this study.  The case-control 
methodology allowed me to compare the HIV CD4s and viral loads of persons coinfected 
with HIV and HBV or HCV with those who are only infected with HIV. The exposure 
variable of interest and will have three categories: HIV only infection, HIV/HCV 
infection, and HIV/HBV infection. The outcome variables of interest were HIV viral load 
suppression and CD4 cell count.  After data collection all exposure variables, HIV only, 
HIV/HCV, and HIV/HBV were evaluated for CD4 cell counts and HIV viral loads.  
Population and Sample 
 The study sample was drawn from reports in the state of Georgia that were 
reported positive for the HIV infection with and without HBV or HCV between the years 
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2012 and 2016. The sample only contained persons aged 18 years and older living in 
Georgia at the time of a positive diagnosis or diagnoses. 
This study used quantitative measures. According to Polit and Beck (2012), 
quantitative research designs often require large samples to increase representativeness 
and reduce sampling error. The sample size is chosen to maximize the chance of 
uncovering a specific mean difference that is statistically significant (Polit & Beck, 
2012).  
 Research data collected in public health practice can be primary or secondary 
(Struwig and Stead, 2001). Secondary data were used for this study. 
The study population was drawn from notifiable disease reports received by the 
GDPH SENDSS and eHARS. Individuals reported to be diagnosed with HBV or HCV 
between the years of 2012 and 2016 was extracted from the SENDSS database and 
matched with prevalent HIV cases in eHARS, a database used to collect information on 
individuals infected with HIV/AIDS. 
Based on the G*Power analysis program using the chi-square statistic with a 
medium effect size of w= 0.30  and an alpha of 0.05, the needed sample size was 94; for a 
small effect size of w= 0.01, the needed sample size would have been 840; and for a large 
effect size of w = .50, the needed sample size would have been 34.   
Data Collection 
The state code grants the GDPH general authority to use surveillance data to 
investigate preventable disease in the state of Georgia. It also permits the GDPH to 
collect personal information and health data for the purpose of surveillance that may 
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prevent and control disease, and it protects the GDPH from civil liability when the data 
are used as required by law for surveillance. Georgia law allows the GDPH to review and 
collect the medical records of any medical facility in Georgia for the purpose of disease 
investigation.  
Access to the data for this study was provided by the GDPH. Permission to use 
the data was granted by the Office of Science, Research, and Academic Affairs in DPH. 
Upon IRB approval from GDPH and Walden University, the HIV data manager at the 
GDPH performed an HIV and hepatitis case match between SENDSS and eHARS for the 
population of coinfected cases. The cases were matched by last name, first name and date 
of birth.  The resulting de-identified dataset of the match was provided for this study.  
The data were presented as a SAS dataset, which included requested variables, and were 
transferred securely to the researcher using a password-protected jump drive and were 
stored in a locked safe at GDPH when not in use.  
The request for HBV, HCV, and HIV data collected through December 2016 was 
submitted to the Georgia DPH in December of 2019. Year-end data of 2016 were the 
most complete CDC approved data for Georgia at the time of the request. The data 
request was approved by the GDPH in February 2020, and the data were received from 
the DPH data submission portal in March 2020. Due to Georgia laws for the protection of 
human subjects, race/ethnicity data were grouped as White, Black, and other, further de-
identifying the data. The dataset was cleaned by deleting all duplicates as well as 
unknowns such as in gender and race.  
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Measures and Variables 
 The information used to create the data set was gathered from disease case 
reports, field records, laboratory reports, and interview records. The last four most recent 
VL counts for the all sample participants were also included in the database for 
assessment of HIV viral suppression. A review of CD4 cell counts was used to 
understand if viral hepatitis impedes the achievement of HIV viral suppression, which is 
defined by the HIV care continuum and CDC as the most recent VL count less than 200 
copies/mL. The care continuum is important in HIV/AIDS data because it allows for 
CDC and other public health agencies to monitor how the United States is doing 
regarding all persons living with HIV, monitor disparities by examining data among sub-
groups of the population, and monitor data at the local level to understand local progress 
and identify additional action steps to meet national level goals. In this study, the care 
continuum definition of viral suppression, was used as a measure to evaluate if HIV is 
affected by HBV or HCV. 
Data Analysis 
Univariate and bivariate analyses were conducted for this study. For all bivariate 
analyses, an alpha value of 0.05 was used to determine whether the observed outcome for 
the specified variables differed significantly from the expected outcome. All statistical 
analyses were carried out using SAS version 9.3. 
External Validity 
The main threat to the external validity of this study may be the sample being 
used from a specific location within the US, so the data may only be applicable to 
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Georgia. The sample will be derived from data reported to the GDPH. Since some 
persons with disease have not been diagnosed or reported, they will not be present in the 
data set. 
Internal Validity 
Possible threats to the internal validity of this study may be the presence of 
confounders, such as other health related outcomes that may or may not influence HIV 
viral suppression, such as other STIs or chronic health conditions. Unfortunately, 
databases which may contain this information are not easily accessible or linked at 
GDPH, but I do not foresee any major threats to the results of this study because of this 
issue.      
Ethical Protection of Participants 
The study proposal was submitted to the Walden GDPH IRB and Walden 
University IRB for review and approval to ensure the adherence to ethical standards and 
federal regulations. Additionally, the GDPH required completion of a data request form 
which also consists of a data use agreement. Identifiers in the data received from GDPH 
were removed by the agency prior to its releasing. This decreased the likelihood of 
having a leak of private health information, which would violate HIPPA regulations. 
Upon completion of the project, the GDPH mandated the return or destruction, by a 





 Observational research was used to determine whether a coinfection with HBV or 
HCV inhibits HIV viral suppression in an HIV infected individual. All exposure variables 
will be evaluated for CD4 cell counts and HIV viral loads. The sample included persons 
18 years or older who were reported and diagnosed with either HIV, HBV or HCV while 
living in Georgia. The dataset was created by GDPH and given to the researcher after 
approval of both DPH and Walden University’s IRB. Data analysis were performed using 




Chapter 4: Results  
Introduction 
This chapter provides the results of a case control study using the data from the 
GDPH on HIV, HBV, and HCV disease reports through the year ending 2016. The 
research questions examines the associations between a coinfection with viral hepatitis 
and HIV viral load suppression in HIV positive individuals and assesses the impact of 
HBV and HCV on CD4 counts in HIV patients. This chapter provides an overview of the 
demographic, HIV viral suppression, and CD4 characteristics of the study sample, 
reviews the research questions and hypotheses, reports the statistical analyses, and 
summarizes the study findings. 
Demographic Characteristics and Results of Bivariate Analysis 
 The study sample included a combined total of 65,626 reports of HIV/HBV (n= 
2,034), HIV/HCV (n= 3,321), and HIV only infected (n= 60, 271). The population 
consisted of 76.3% males and 23.4% females. Age was stratified into five categories: 
10.3% were between the ages of 20 years and 29 years; 22% were between the ages of 30 
years and 39 years; 22.1% were between the ages of 40 years and 49 years; 28.1% were 
between the ages of 50 years and 59 years; and 17.5% were aged 60 years and older. 
Regarding race/ethnicity, 68% of the study population were non-Hispanic African 
American, 18% were non-Hispanic White, and 14% were defined as Other. The 
demographic characteristics for each category of the exposure variables (HIV/HBV, 





Demographic Characteristics by Disease Status 
 HIV/HBV HIV/HCV HIV only 
Gender    
   Males 1,778 2,570 45,203 
   Females 236 723 14,381 
    
Race    
   White  360  609  10,861 
   Black  1,437  2,302  44,591 
   Other  237  3,321  8,558 
    
Age (yrs)    
   20-29  66  138 6,563 
   30-39  360  456 13,512 
   40-49  597  574 13,313 
   50-59  690  1,109 16,610 
   ≥60  314  1,041 10,071 
    
Risk factor    
   *MSM 1486 1654 36,916 
   *IDU 96 627 3,550 
Note. N=65,626 *MSM=Men who have sex with men *IDU= Intravenous drug user 
 
Research Questions and Hypotheses Testing 
To answer the research questions, each hypothesis was tested to assess the 
potential associations between the exposure variable and outcome variables. For each of 
the hypotheses, a Pearson Chi-square analysis and measure of associations are presented 
below.  
RQ1: Is there an association between coinfection with viral hepatitis and HIV 
viral load suppression in HIV positive individuals? 
Ho1: There is no association between coinfection with viral hepatitis and HIV 
viral load suppression in HIV positive individuals. 
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Ha1: There is an association between coinfection with viral hepatitis and HIV 
viral load suppression in HIV positive individuals.  
Results suggest that people with coinfection (HIV/HBV and HIV/HCV) had more 
HIV viral suppression than those who were only infected with HIV (Figure 1). 
Individuals who were coinfected with HIV and HBV were more likely to have achieved 
HIV viral load suppression than individuals who were only infected with HIV (OR=1.45, 
95% CI 1.32-1.59, p= .0001). A similar observation was seen for individuals who were 
coinfected with HIV and HCV (OR= 1.55 95% CI 1.44-1.67, p= .0001). Therefore, I 
rejected the null hypotheses which stated that there is no association between coinfection 
with viral hepatitis and decreased HIV viral load suppression in HIV positive individuals.  
 



















HIV/HBV HIV/HCV HIV Only
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RQ2: Does the type of viral hepatitis (HBV or HCV) impact the CD4 count of the 
HIV infection?  
Ho2: The type of viral hepatitis (HBV or HCV) does not impact the CD4 count of 
the HIV infection. 
Ha2: The type of viral hepatitis (HBV or HCV) impacts the CD4 count of the HIV 
infection. 
 HIV/HBV occurrences and HIV/HCV occurrences were evaluated to determine 
the impact of HBV and HCV on HIV CD4 cell count. HIV CD4 cell count was measured 
based off the AIDS defining definition, a CD4 cell count which drops below 200 
cells/mL. When the three categories HIV/HBV, HIV/HCV & HIV only were compared, 
the percentage of AIDS defining occurrences, as of year-end December 2016, was greater 
in individuals coinfected with HIV/HBV and HIV/HCV than those only infected with 





Figure 2.  AIDS defining diagnoses by disease status year-end December 2016. 
 
When the CD4 cell counts of HIV/HBV coinfected individuals were compared to 
the CD4 cell counts of HIV/HCV coinfected individuals using the HIV care continuum 
time points (3 months after HIV diagnosis, 12 months after HIV diagnosis, and current 
year-end), there was a significant difference in the amount of AIDS defining cases. At all 
time frames, HIV/HBV coinfected individuals were more likely to have low CD4 cell 
counts, (AIDS defining), than HIV/HCV coinfected individuals (Table 2). Therefore, the 
H02 null hypothesis which states that the type of viral hepatitis (HBV or HCV) does not 























AIDS Defining at Care Continuum Time Points 
AIDS (%) HIV/HBV HIV/HCV OR (95% CI) 
3 Months    
     χ2= 24.8  
 
20.63 15.32 *1.44(1.23,1.74) 
12 Months    
     χ2= 31.1 24.01 17.72 *1.47(1.31,1.71) 
    
Year-end December 2016    
     χ2= 39.1 68.71 60.31 *1.45(1.34,1.67) 
Note. * p < .001  
Summary 
The study findings were presented in this chapter. This included a demographic 
summary of the study population. Both research questions were assessed to determine the 
variables significantly associated with HIV viral load suppression and HIV CD4 cell 
counts. In research question one, a coinfection with HBV and HCV was determined to be 
associated with HIV viral load suppression when compared to individuals only infected 
with HIV. In research question two, a coinfection with HBV was found to have a greater 
impact on CD4 cell counts in all time frames of the HIV care continuum than a 
coinfection with HCV in individuals infected with HIV.  Chapter 5 provides a discussion 
of the findings, limitations of the study, recommendations for future research, as well as 
implications for social change.  
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Chapter 5: Discussion, Conclusions, and Recommendations 
Introduction 
This study had two major purposes. The first was to assess whether an infection 
with viral hepatitis B or C hinders HIV viral suppression when present concurrently in 
individuals. The second was to assess which hepatitis type (HBV or HCV) had a greater 
impact CD4 cell counts in an HIV infected individual. In this chapter, I describe the 
results of the study to demonstrate that the purpose was achieved. Chapter 5 includes a 
discussion of the study findings, recommendations for further, and the conclusion to this 
study. 
Discussion and Interpretation of Findings 
 A significant finding of this study was that persons who were either coinfected 
with HBV (OR= 1.45) or HCV (OR=1.55) were more likely to be HIV virally suppressed 
than those persons who were only infected with HIV. In a study which looked at the 
relationship of HIV viral load suppression and infection with HCV, persons coinfected 
with HCV/HIV were two times more likely to have achieved HIV viral load suppression 
than persons who were only infected with HIV, considering good adherence to HIV 
treatment (OR= 2.05, 95% CI 1.23-3.43, p= 0.006; Bani-Sadr et al., 2014). Good 
adherence to HIV treatment, ART, is essential in the HIV infection in that it suppresses 
the HIV viral load, restore or preserve immunologic function, and improves the infected 
person’s quality of life by reducing the risk of HIV-related morbidity and mortality. The 
results of this study could be explained by a greater adherence to ART in the HBV and 
HCV coinfected population. Because persons coinfected with viral hepatitis and HIV are 
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more likely to have unfavorable health outcomes than persons infected with HIV only, 
they may be more likely to adhere to HIV therapy guidance due to the presence of more 
than one infection.  
 In the current study, persons who were coinfected with HBV (OR= 2.12) or HCV 
(OR= 1.46) were significantly more likely to have a CD4 cell count below 200cells/ml, 
AIDS defining, than persons who were infected with HIV only. AIDS defining cases 
were found in 66.6% of persons coinfected with HIV/HBV, 58.5 % of persons coinfected 
with HIV/HCV, and 50.5% of persons only infected with HIV. This finding is consistent 
with those of several studies (Salmon-Ceron et al., (2005); Sherman et al., (2002); Rana 
et al., 2019). As mentioned, HIV is defined as AIDS when an individual’s CD4 cell count 
drops below 200 cells/ml at any time during the HIV infection. Piroth et al., (1998), Grub 
et al., (2014), and Van Santen et al., (2019) evaluated the progression of AIDS in persons 
coinfected with HBV or HCV and observed a decrease in CD4 cells by at least 60% in 
coinfected persons in compared to persons only infected with HIV. The current study 
finding may indicate that HBV and HCV negatively impact the HIV infection when 
concurrently present. This could also explain why persons coinfected with HIV/HBV or 
HIV/HCV are more likely to be HIV virally suppressed than those infected with HIV 
only. Persons who are defined as an AIDS case may be more likely to adhere to ART 
guidance due to the severity of their HIV infection. Without proper treatment adherence, 
persons diagnosed with AIDS typically have a survival time frame of 3 years.  
Those who were HBV/HIV coinfected were significantly more likely to be AIDS 
defining at all time points of the HIV care continuum than HCV/HIV coinfections. This 
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could be a result of the high prevalence of men who have sex with men (MSM) among 
those who are infected with HIV. The proportion of MSM who have HIV is higher than 
any other group in the US. In 2016, more than half of the HIV infected population 
identified as being MSM (CDC, 2020). Since HBV is a common coinfection with HIV, 
MSM are disproportionately affected by HBV, with 15-25% of new infections occurring 
in this group (Falade-Nwulia et al., 2015). Eskild et al. (2012) looked at the previous and 
current HBV infection in HIV disease progression and found that the presence of HBV 
antibodies was associated with more rapid HIV disease progression. MSM who were 
HBV/HIV infected had a three-time risk of progression to AIDS compared to the 
individuals who were only infected with HIV. Also, like the current study, Japhet et al. 
(2016), which investigated HIV viral loads in the presence of HBV, found that although 
HBV/HIV persons had adequate viral suppression rates, the HBV coinfection was 
associated with increased progression to AIDS. 
Support for the Theoretical Framework 
 The results of this study indicated that HBV and HCV do not hinder HIV viral 
load suppression in persons infected with HIV, but the two viruses are associated with 
more rapid progression to AIDS when a person is concurrently infected with HIV. This 
finding is important because it highlights how HBV and HCV can cause excess morbidity 
and mortality in persons infected with HIV. In the syndemic theory, the concept 
syndemic refers to the tendency for multiple epidemics to co-occur and interact with each 
other and worsen the others’ effects (Singer, 2009). The syndemic theory is a valuable 
tool in the public health fight against HIV. The theory reveals how important focused 
50 
 
prevention and control measures are for each disease that plays a role in the syndemic as 
well as the prevention and control of the mechanisms that bring the two diseases together.   
 The current study provided evidence of the excess burden that HBV and HCV 
may cause when present with HIV. Given this evidence, there should be more efforts 
towards the creation of public health initiatives to address and lessen the impact of HBV 
and HCV in HIV infected individuals.    
Limitations 
 The dataset included information from two databases, SENDSS (HBV and HCV 
diagnoses) and eHARS (for HIV diagnoses). The two databases contain information on 
all persons in Georgia who were tested and diagnosed with either HIV or HBV or HCV. 
While both hepatitis and HIV are reportable diseases under Georgia law, there was no 
way to guarantee that the data from diagnoses utilizing private insurance and diagnosed 
with HIV and/or hepatitis had been captured, so they could potentially have been missing 
from the databases. Additionally, people who were positive for HIV and/or hepatitis but 
had never been tested were not represented in the dataset. While frequencies of 
underreporting of HIV and hepatitis diagnoses in Georgia were not available, the GDPH 
did acknowledge that underreporting may be a limitation of the data available in their 
databases. 
 Another limitation included the incompleteness of data on Georgia’s HIV reports. 
When diagnoses are reported by providers, often information regarding gender, risk 
factors, as well as whether the individual is on ART is missing from the report. This 
reduces the ability to capture a complete profile of the HIV reports in Georgia. It also 
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limits the ability to understand how effective ART is on HIV viral suppression. Because 
scientific data has shown that consistent HIV treatment is key for HIV viral suppression, 
Georgia can only assume that individuals who were virally suppressed were consistently 
taking ART.   
 Because hepatitis data and HIV data are housed in two separate databases, a 
manual match between the two databases had to be performed to identify the people with 
coinfections. Because the hepatitis database also experiences underreporting, there were 
several gaps in identifying cases for inclusion as a coinfected diagnoses. Diagnoses with 
hepatitis infection and undiagnosed HIV infection would not be included, and diagnoses 
with HIV infection and undiagnosed hepatitis infection would also not be included in the 
study database.  
Finally, there may have been overlap with successfully treated hepatitis infection 
and subsequently diagnosed HIV infection. Unlike HIV data, hepatitis data are not 
continuously reported with updated lab data. So ultimately there is no way to identify if a 
case which was reported as HBV or HCV positive had been successfully treated and 
cleared or if the case was not treated and became a chronic hepatitis infection. 
 
Recommendations for Future Research 
Due to data limitations, the current study was unable to verify the HIV treatment 
status of the cases. To assess if the HIV/hepatitis coinfected individuals are more likely to 
be HIV virally suppressed than individuals infected with HIV only due to their likelihood 
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of adhering to HIV treatment, future research on ART adherence in this population is 
recommended.   
It is likely that socioeconomic confounders existed among the individuals in the 
current study that predisposed them to be susceptible to a more rapid progression to 
AIDS. Such socioeconomic confounders could be education, employment status, 
occupation, income level, and presence/absence of insurance. These variables are not 
collected as part of GDPH disease surveillance. Future research should consider 
collection of such socioeconomic variables to minimize the effects of confounding due to 
these factors. 
Recommendations of Action 
 Possibly one of the greatest approaches to reduce the incidence of the 
HBV/HCV/HIV coinfection is screening. HIV infected persons should be screened 
regularly for HBV and HCV coinfections and advised about prevention, especially in 
high-risk groups such as MSM and IDUs. Sexual transmission of HBV and HCV should 
be included in counseling for HIV infected persons. Increased progression rates to AIDS 
in the coinfected population may require earlier and advanced treatment of both 
infections.  
Implications for Social Change 
The current study has shown evidence that HIV viral suppression rates are higher 
in the HBV/HCV/HIV coinfected population; however, it also revealed that this 
population is more prone to rapid progression to AIDS. CD4 cell counts, which are used 
as indicators of AIDS, are relative predictors of mortality in persons infected with HIV, 
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regardless of how long treatment has been administered or whether a person is currently 
HIV virally suppressed (Brennan et al., 2013).  Data from the current study could be used 
to support an increase in screening, diagnosis, and access to treatment to properly care for 
the HIV/HBV/HCV coinfection population.   
Conclusion 
 The HBV/HCV/HIV coinfection has become increasingly common within the 
HIV population. The coinfection of these viruses increases the morbidity and mortality 
beyond those caused by either infection alone. The current study has provided insight that 
the HBV/HCV/HIV coinfected population is at greater risk of progression to AIDS than 
those only infected with HIV. This alone is a major public health threat. A better 
understanding of the interactions between these viruses is critical to the development of 
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